Posted on November 21, 2007 by Trevor Butterworth
Trevor Butterworth
On October 18, The European Medicines Agency announced (pdf) that “having assessed all the data,” the benefits of the antidiabetic medicine Avandia (along with rival Actos) outweighed the risks. The Agency added:
“However, the prescribing information should be updated to include a warning that, in patients with ischaemic heart disease, rosiglitazone [Avandia] should only be [...]
Filed under: Avandia, Diabetes, Endocrinology, Food and Drug Administration, Pharmaceuticals, Risk | Tagged: Chuck Grassley, enate Finance Committee, Glaxo, GSK, John Buse, Max Baucus, Tadataka Yamada | No Comments »
Posted on November 12, 2007 by Trevor Butterworth
Trevor Butterworth
Undoubtedly New York Times reporter Gardiner Harris knows how to report; and, it is reasonable to presume that his editors – who provide the six layers of editing that every Times article must endure - recognize good reporting when they see it. The problem with Gardiner’s coverage of the various controversies surrounding the diabetes [...]
Filed under: Avandia, Diabetes, Food and Drug Administration, Pharmaceuticals | Tagged: Gardiner Harris, New England Journal of Medicine, New York Times, Steve Nissen | No Comments »
Posted on November 9, 2007 by Trevor Butterworth
Trevor Butterworth, Huffington Post
As another major scientific journal criticizes the methodology behind a study in the New England Journal of Medicine (NEJM) that prompted a nationwide panic over a popular diabetes drug, it turns out that the doctor who authored the study, Steven Nissen MD, delivered a blistering attack on those very methods seven years [...]
Filed under: Avandia, Diabetes, Meta Analysis, Pharmaceuticals, Statistical Analysis, risk analysis | Tagged: Avandia, heart attack, New England Journal of Medicine, Steve Nissen | No Comments »
